Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Gyo Asai(Aichi Cancer Center), Kozo Yoshimori(Japan Anti Tuberculosis Association), Shunichiro Iwasawa(Chiba University), Haruhiro Saito(Kanagawa Cancer Center), Ou Yamaguchi(Saitama International Medical Center), Futoshi Kurimoto(Saitama Cancer Center), Koichi Azuma(Kyushu University Hospital), Yukari Tsubata(Shimane University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Hiromi Nagashima(Iwate Medical University), Naoki Furuya(St. Marianna University School of Medicine), Yoshio Tsunezuka(Ishikawa Prefectural Central Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Masaki Miyazaki(Suita Municipal Hospital), Yuka Fujita, Prof Satoshi Morita(Kyoto University), Prof Kunihiko Kobayashi(Saitama Medical University), Prof Toshihiro Nukiwa(Tohoku University), Prof Koichi Hagiwara(Jichi Medical University), Kana Watanabe(Miyagi Prefectural Hospital Organization), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Prof Morihito Okada(Hiroshima University Hospital), Akihiko Gemma(Nippon Medical School)
Cited by 30
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695